Novo Nordisk’s Amycretin Achieves Up to 22% Weight Loss in …
3 days ago · The 20 mg amycretin group lost 22% of body weight at 36 weeks compared with a 2% weight gain with placebo in Part C. 1. The safety profile of amycretin was consistent with other incretin-based therapies, with gastrointestinal events being the most commonly reported. Most adverse events were mild to moderate in severity, reported Novo Nordisk. 1
Amycretin - Wikipedia
Amycretin is a single molecule that operates as a GLP-1 receptor agonist and amylin receptor agonist. It is under development by Novo Nordisk as a weight loss drug; unlike some competitors, it can be delivered orally.
Subcutaneous Amycretin Yields Promising Weight Loss in Phase …
3 days ago · Topline data from a Phase 1b/2a clinical trial were positive for once-weekly subcutaneous amycretin, a glucagon-like peptide-1 (GLP-1) and amylin receptor agonist intended for the treatment of overweight or obesity. 1. Announced by Novo Nordisk on January 24, 2025, amycretin demonstrated a safety profile similar to other incretin-based therapies, with an estimated body weight loss of up to 22% ...
Weight loss: Amycretin pill may be more effective than semaglutide
Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity —...
Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight …
3 days ago · On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...
Novo shares climb on early data for dual-acting obesity drug
3 days ago · Amycretin affects the same two targets as a Novo drug called cagrisema that recently missed expectations in a Phase 3 trial, but does so in a single molecule rather than a two-drug combination. Novo shares, which fell sharply on the cagrisema news, rose as much as 11% in before settling into an 8% gain midday Friday.
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
Mar 8, 2024 · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.
Experimental Oral Drug Shows 'Remarkable' Weight Loss, Novo …
Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain, rather than in the gut.
'Remarkable' Weight Loss With Novel Oral Combo in Phase 1
Sep 12, 2024 · Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.
Novo Nordisk’s Amylin Pill Is Fast-Acting, Longer ... - Healthline
Sep 12, 2024 · Novo Nordisk is testing a new weight-loss pill, called amycretin, that is said to lead to faster, more significant weight loss than currently approved GLP-1 injectable medications like...
- Some results have been removed